Search this site

Generative AI analyzes medical data faster than human research teams. That was the central finding from a new study led by scientists at the University of California, San Francisco and Wayne State University, offering one of the earliest real-world tests of generative AI in health research. In a head-to-head comparison, researchers assigned identical analytical tasks to multiple groups. Some relied entirely on human expertise. Others paired scientists with generative AI tools. The challenge: predict preterm birth using data from more than 1,000 pregnant women. Human experts had previously spent months analyzing the same information. By contrast, AI-supported teams were able to generate functioning analytical code in minutes. A Junior Team, Powered by AI Notably, even a junior research pair, a UCSF master’s student and a high school student, successfully developed prediction models with AI assistance. The advantage stemmed from AI’s ability to write analytical code based on short but highly specific prompts. Performance, however, was not universal. Only four of the eight AI chatbots tested produced usable code. Still, the systems that succeeded did not require large teams of specialists to guide them. Because of this acceleration, the junior researchers were able to complete their experiments, verify their findings, and submit results to a journal within just a few months. “These AI tools could relieve one of the biggest bottlenecks in data science: building our analysis pipelines,” said Marina Sirota, professor of Pediatrics who is the interim director of the Bakar Computational Health Sciences Institute (BCHSI) at UCSF and the principal investigator of the March of Dimes Prematurity Research Center at UCSF. “The speed-up couldn’t come sooner for patients who need help now.” The study was published in Cell Reports Medicine on Feb. 17. Why Preterm Birth Research Matters The implications extend beyond technical efficiency. Preterm birth remains the leading cause of newborn death and contributes significantly to long-term motor and cognitive challenges in children. In the United States alone, roughly 1,000 babies are born prematurely each day. Despite decades of research, scientists still do not fully understand what causes preterm birth. To investigate potential risk factors, the research team compiled microbiome data from approximately 1,200 pregnant women across nine separate studies. “This kind of work is only possible with open data sharing, pooling the experiences of many women and the expertise of many researchers,” said Tomiko T. Oskotsky, MD, co-director of the March of Dimes Preterm Birth Data Repository, associate professor in UCSF BCHSI, and co-author of the paper. However, analyzing such vast and complex datasets presents its own bottlenecks. To address this, researchers turned to DREAM (Dialogue on Reverse Engineering Assessment and Methods), a global crowdsourcing competition designed to tackle difficult biomedical data challenges. More than 100 teams worldwide participated in pregnancy-related DREAM challenges, developing machine learning models to detect patterns linked to preterm birth. Most teams completed their work within three months. Yet consolidating findings and publishing results ultimately took nearly two years. Testing AI on Pregnancy and Microbiome Data Curious whether generative AI could shorten that timeline, the UCSF team partnered with researchers at Wayne State. Together, they instructed eight AI systems to independently generate algorithms using the same DREAM datasets, without direct human coding. The AI chatbots received carefully written natural language prompts, guiding them to analyze vaginal microbiome data for signs of preterm birth and to examine blood or placental samples to estimate gestational age. Pregnancy dating is almost always an estimate, yet it determines the type of care women receive as pregnancies progress. Inaccurate estimates can complicate labor preparation and clinical decision-making. When researchers executed the AI-generated code, four of the eight tools produced models that matched the performance of human teams. In some cases, the AI models performed better. Importantly, the entire generative AI effort—from inception to submission of a paper—took just six months. AI as a Research Accelerator Scientists caution that AI systems still require careful oversight. Generative models can produce misleading or flawed outputs, and human expertise remains essential for interpretation and validation. Still, the productivity gains are difficult to ignore. “Thanks to generative AI, researchers with a limited background in data science won’t always need to form wide collaborations or spend hours debugging code,” said Adi L. Tarca, PhD, professor at Wayne State University. “They can focus on answering the right biomedical questions.” For investors and healthcare stakeholders, the study signals more than incremental improvement. If generative AI continues to compress research timelines it could materially accelerate drug discovery, diagnostics development, and translational medicine. In a sector where time-to-insight often translates directly into patient outcomes and commercial opportunity, that shift may prove transformative.

The U.S. Department of Energy is backing new projects to recover critical minerals from coal waste, turning an old industrial byproduct into a potential new supply chain opportunity. The U.S. Department of Energy is putting fresh money behind an unexpected source of critical minerals: coal waste. The agency has awarded $7.5 million in funding to projects focused on recovering valuable minerals and rare earth elements from coal feedstocks, coal ash, and other mining byproducts. While the funding amount is modest, the message is bigger — Washington is looking for more ways to build domestic supply chains for materials that power the modern economy. Critical minerals are used across some of today’s fastest-growing industries, including electric vehicles, semiconductors, defense systems, energy infrastructure, and advanced manufacturing. Instead of relying only on new mines, the U.S. is now exploring whether older coal materials can be turned into a new strategic resource. That shift matters for investors. Coal waste has traditionally been viewed as an environmental and industrial liability. But if companies can recover valuable materials from existing byproducts, it could create a lower-cost pathway into the critical minerals market. The funding also comes as the U.S. works to reduce dependence on foreign mineral supply chains, particularly for resources tied to national security and long-term industrial competitiveness. For markets, the bigger story is that critical minerals are becoming too important to ignore. Demand is being driven by AI infrastructure, battery production, grid expansion, defense technology, and advanced electronics. As that demand grows, investors are watching companies involved in extraction, processing, recycling, and mineral recovery more closely. The Department of Energy’s latest move shows how the critical minerals race is expanding beyond traditional mining. Waste recovery, recycling, and alternative extraction technologies are becoming a bigger part of the supply chain conversation. For Wall Street, the takeaway is simple: the next opportunity in critical minerals may not just come from new mines. It could also come from materials America has already pulled out of the ground.

Renalytix shares surged 24% after new two-year clinical data reinforced the effectiveness of its AI-powered KidneyIntelX test. More importantly for investors, the results strengthen the company’s commercial case, shifting the focus from proving the science to proving the business. Clinical breakthroughs don’t always send shares soaring. But when new data strengthens a company’s path to commercial success, investors take notice. That’s exactly what happened to Renalytix, whose shares climbed 24% after the healthcare diagnostics company released positive two-year clinical data for its flagship KidneyIntelX test. While the rally grabbed headlines, the real story is what the results could mean for the company’s long-term growth. KidneyIntelX is an AI-powered diagnostic test designed to identify patients at high risk of developing progressive kidney disease before serious complications occur. By combining blood biomarkers, patient medical records and artificial intelligence, the test helps physicians identify which patients are most likely to see their condition worsen, allowing treatment to begin earlier. The latest two-year follow-up data showed that KidneyIntelX continued to accurately identify patients who went on to experience worsening kidney disease. For healthcare providers and insurers, that kind of long-term validation is critical. Strong clinical evidence is often a key factor in deciding whether a new technology becomes part of everyday patient care. For investors, that’s where the opportunity begins. Renalytix isn’t being valued solely on today’s financial performance it’s being valued on its ability to turn proven science into a scalable healthcare business. Every successful clinical milestone helps reduce uncertainty, strengthens the company’s commercial case and improves its ability to win new hospital customers, reimbursement agreements and strategic partnerships. The addressable market is substantial. Chronic kidney disease affects millions of people worldwide, yet many patients are diagnosed only after irreversible damage has occurred. A diagnostic tool capable of identifying high-risk patients earlier has the potential to improve patient outcomes while reducing long-term healthcare costs a combination that healthcare systems are increasingly looking for. Of course, strong clinical data doesn’t guarantee commercial success. Renalytix still needs to prove it can expand adoption of KidneyIntelX, grow recurring revenue and move closer to profitability. Many healthcare technology companies have demonstrated impressive science but struggled to translate that into meaningful financial results. The next phase of the company’s journey will be determined not in the laboratory, but in hospitals, clinics and boardrooms. The market’s 24% reaction suggests investors believe Renalytix has taken another meaningful step in that direction. The latest results don’t just reinforce confidence in KidneyIntelX they strengthen confidence that the company has a product capable of becoming a valuable part of future kidney disease care. Investor Takeaway This wasn’t simply a stock reacting to positive news it was investors reassessing Renalytix’s long-term commercial potential. The company’s latest data removes another layer of uncertainty around KidneyIntelX and reinforces the investment case, but the focus now shifts to execution. Investors should watch closely for accelerating adoption, additional reimbursement wins, new commercial partnerships and, ultimately, sustained revenue growth. If Renalytix can convert clinical success into commercial momentum, this week’s rally could prove to be the start of a much larger story.

Regional banks are emerging as potential new players in the crypto industry as digital assets move closer to the financial mainstream. The shift could create fresh growth opportunities for smaller lenders looking to expand beyond traditional banking services. For years, the crypto industry operated largely outside the traditional banking system. Now, that relationship may be starting to change and smaller U.S. banks could become some of the biggest beneficiaries. As digital assets continue moving closer to the financial mainstream, regional and community banks are increasingly being viewed as potential partners for crypto companies searching for reliable banking services. The shift comes after the collapse of several major crypto-friendly banks left a gap in the market and forced many digital asset firms to rethink how they interact with traditional finance. Crypto companies still rely heavily on banking infrastructure for payments, deposits, payroll, and customer transactions. But large financial institutions have often remained cautious toward the sector due to regulatory uncertainty and the volatility surrounding digital assets. That has opened the door for smaller banks looking for new growth opportunities. For regional lenders facing slower growth and rising competition, crypto-related business could offer a way to attract deposits, expand services, and position themselves within a fast-growing part of the financial industry. The development also highlights a broader shift taking place across the market. Crypto is increasingly evolving from a standalone industry into a larger financial infrastructure story tied to banking, payments, stablecoins, and digital transactions. As regulation becomes clearer, more traditional financial institutions may begin exploring how digital assets fit into their long-term strategies. Investors are paying close attention because the trend could reshape parts of the American banking landscape over time. Still, risks remain significant. Regulatory pressure, compliance costs, and ongoing volatility in crypto markets continue to create uncertainty for banks considering deeper involvement in the sector. Analysts have also warned that many financial institutions remain cautious after the banking turmoil tied to crypto markets in recent years. Even so, momentum appears to be building toward greater integration between crypto and traditional finance. And for some regional banks, that shift could create an unexpected new growth opportunity. Source: Yahoo Finance/Simply Bitcoin. Not paid promotion.

AI bubble concerns appear to be easing in market behaviour, according to the BIS, despite elevated AI-linked valuations. The report notes a lack of typical bubble stress signals, with continued inflows into AI stocks and limited risk-off positioning. It also highlights AI being increasingly treated as a structural growth theme, alongside ongoing debate around valuations and market concentration. The debate around whether artificial intelligence is forming a market bubble continues to divide analysts, but a new assessment from the Bank for International Settlements suggests a shift in how markets are currently behaving. In commentary highlighted by Reuters, the Bank for International Settlements the global financial institution often described as a “central bank for central banks” noted that concerns around an AI-driven market bubble appear to be losing traction in actual trading behaviour, even as valuations in the sector remain elevated. The remarks come at a time when AI-linked equities have been one of the dominant forces in global equity markets, with investor attention heavily concentrated on a small group of large-cap technology companies tied to artificial intelligence infrastructure, semiconductors, and cloud computing. Market behaviour vs market narrative The BIS framing draws a distinction between sentiment in financial commentary and what is being observed in broader market conditions. While discussions around potential overvaluation in AI-related assets have persisted throughout 2025 and into 2026, the BIS indicated that market indicators do not currently reflect rising systemic stress typically associated with speculative bubbles. In particular, the commentary points to a lack of: Sharp increases in financial market volatility Broad-based risk-off positioning across asset classes Credit market stress consistent with speculative excess Instead, AI-linked equities have continued to attract inflows, with dips in major technology names often being met with renewed buying activity rather than sustained liquidation. AI sector positioned as structural growth theme According to the BIS perspective, part of the explanation lies in how markets are increasingly classifying artificial intelligence within long-term economic frameworks. Rather than being treated solely as a short-term speculative cycle, AI is increasingly viewed by investors as a structural productivity theme, alongside previous technological shifts such as cloud computing and internet infrastructure expansion. This positioning has contributed to sustained capital allocation into: Semiconductor manufacturers Data infrastructure providers Cloud computing platforms AI model developers and related software firms The effect has been continued concentration in equity indices, particularly in the United States, where a limited number of large technology companies account for a significant share of index performance. Valuations remain central to the debate Despite the more stable market behaviour highlighted in the BIS commentary, valuation levels across parts of the AI sector remain a central point of discussion among analysts. Some market participants continue to point to elevated price-to-earnings ratios in leading AI-related companies, alongside strong forward expectations for revenue growth. Others argue that these valuations are being supported by rapid adoption rates and expanding demand for AI infrastructure. The BIS does not take a position on whether current pricing levels are justified, instead focusing on the absence of typical pre-crisis financial market signals. Broader macro context The commentary also sits within a wider macroeconomic environment in which equity markets have been shaped by: Interest rate expectations shifting across major central banks Continued investment in digital infrastructure Corporate capital expenditure tied to AI deployment These factors have contributed to a market environment where growth sectors remain dominant drivers of index performance, even as broader economic conditions vary across regions. Bottom line The BIS analysis, as reported by Reuters, presents a picture in which AI-related market enthusiasm remains intact, while traditional indicators of speculative overheating are not currently evident in broader financial conditions. At the same time, the ongoing discussion around valuation, concentration, and long-term earnings expectations suggests the AI sector will remain a focal point for both investors and policymakers.

Utah critical minerals strategy is moving from policy concept to execution. State leaders have unveiled a coordinated plan to make Utah the top destination for critical mineral extraction and processing in the country, a move that could directly support Washington’s broader effort to secure supply chains essential to defense, energy, and advanced manufacturing. At the center of the initiative is Utah Governor Spencer Cox’s newly revealed “Mission Critical” framework, which sets aggressive targets: meeting 25% of U.S. critical mineral demand, cutting permitting timelines by half to under 18 months, and ensuring that at least 50% of mined materials are processed within the state. Why Utah and Why Now The U.S. remains fully dependent on foreign sources for a dozen critical minerals and sources more than half of its supply for 21 others from China. Beijing controls roughly 70% of global rare earth mining and more than 80% of processing for materials such as cobalt, battery graphite, and rare earth elements. Against this backdrop, Utah’s political leadership sees an opening. Senate President Stuart Adams framed the strategy as a direct response to trade and tariff pressures, arguing that domestic supply is a practical solution to geopolitical risk. The Trump administration’s decision to delay certain tariffs on critical minerals underscores how constrained domestic supply has become, and how valuable credible U.S.-based alternatives may be. Accelerating Projects and Permitting One of the most notable elements of the Mission Critical plan is speed. Utah aims to approve five critical mineral mining projects within the next 18 months, while simultaneously modernizing permitting processes without lowering safety or environmental standards. Governor Cox has pointed to lessons learned from mining-heavy jurisdictions like Canada and Australia, following trade missions in 2025. “I‘m working … on significantly lowering the time frame that it takes for permitting, in both the mining area and the processing of critical minerals,” Cox said. “(And) still keeping people safe. We can do both of those things.” Industry groups appear aligned. Brian Somers, president of the Utah Mining Association, described the plan as the result of months of collaboration between government, academia, and the private sector. “Utah has all of the components needed to be a global leader on this,” Somers told news outlet Deseret News. “I really do think that Utah can take a leading role in helping to solve this problem for the U.S. and also for the industrialized world so that we’re not reliant on China for these mineral supply chains.” Beyond extraction, Utah is emphasizing downstream value. The framework proposes the creation of critical mineral processing zones, enhanced tax incentives, and a dedicated funding stream sourced from severance taxes. Perhaps the most strategic element is the push to establish a U.S. Critical Minerals National Laboratory in Utah within six years. Associated Universities, Inc., an operator of major federal research facilities, has already identified Utah as the preferred location. The proposed MINES Center at the University of Utah would anchor research, workforce development, and innovation in mineral processing. State leaders say discussions with federal partners, including the Department of the Interior and the White House, are already gaining traction. Geological Advantage Meets Policy Support Utah’s geological credentials strengthen the case. The Fraser Institute ranked the state as the world’s top jurisdiction for mining investment in 2024, citing both policy stability and resource potential. Utah is currently the only U.S. producer of beryllium concentrate, potassium sulfate, and uintaite, and hosts 50 of the 60 minerals on the federal critical minerals list. Recent discoveries add momentum. Ionic Mineral Technologies’ Silicon Ridge project in Utah County contains halloysite-hosted ion-adsorption clays – geologically similar to deposits that account for roughly 40% of China’s rare earth production. State leaders suggest processing could begin as early as this spring. Economic Strategy Beyond Mining Lawmakers are also framing critical minerals as an economic hedge. House Speaker Mike Schultz has warned that AI-driven disruption could pressure Utah’s tech employment base, making energy, mining, and processing long-term stabilizers for the state economy. From a broader perspective, Utah’s strategy reflects a growing recognition that critical minerals are not just a resource issue, but an industrial policy issue, one that ties together defense readiness, trade leverage, and economic resilience. Schultz adds, “I predict that energy and critical minerals will play a key role in being one of the leading drivers of the state’s economic development down the road.”

U.S. oil companies are expected to post sharply higher profits as stronger crude prices and summer fuel demand boost the energy sector, even as rising gasoline prices begin attracting renewed political pressure in Washington. America’s largest oil companies are expected to report a major jump in profits as stronger crude prices and resilient fuel demand continue boosting the energy sector even as rising gasoline prices begin drawing renewed political scrutiny. According to Reuters, major U.S. energy producers and refiners are benefiting from improved market conditions heading into the second half of 2026, with higher oil prices and stronger refining margins helping lift earnings across the industry. The rebound comes as global energy markets remain tighter than many analysts expected earlier this year. Summer travel demand, ongoing geopolitical uncertainty, and disciplined production levels from major oil-producing nations have all helped support crude prices, creating favorable conditions for companies including Exxon Mobil, Chevron, and ConocoPhillips. But the improving outlook for oil companies is also creating growing political tension in Washington. President Donald Trump has reportedly increased pressure on the industry over gasoline prices as higher costs at the pump once again become a concern for consumers. Fuel prices remain one of the most visible indicators of inflation for American households, and sustained increases can quickly affect consumer sentiment and broader economic confidence. That dynamic has historically placed oil companies in the political spotlight during periods of elevated energy prices, particularly during peak driving seasons. For investors, the story highlights how the energy sector continues benefiting from a market environment that remains heavily dependent on fossil fuels despite ongoing global investment into renewable energy and electrification. The latest earnings expectations also reinforce the growing divide currently shaping global markets. While artificial intelligence and technology stocks continue dominating investor attention, traditional energy companies are quietly generating some of the strongest cash flows in the market as global oil demand remains resilient. The situation also underscores the increasingly difficult balance facing policymakers. Lower fuel prices can help ease inflationary pressure and support consumers, but tighter energy markets continue rewarding producers and shareholders with stronger profitability. If oil prices remain elevated through the second half of the year, energy stocks could continue outperforming broader market sectors while also complicating expectations for future interest rate cuts. As markets head deeper into earnings season, investors will be closely watching whether major oil producers signal confidence in sustained demand or warn that rising political pressure could eventually weigh on the sector.

FDA approval of America’s first mRNA flu vaccine gives Moderna its clearest opportunity yet to build a lasting pharmaceutical business beyond Covid. Moderna has spent years trying to prove that mRNA technology can support a lasting pharmaceutical business beyond the pandemic. Its newly approved flu vaccine may be its most important opportunity yet. The US Food and Drug Administration has approved mFlusiva for adults aged 50 and older, making it the first mRNA-based seasonal flu vaccine authorised in the country. The approval was supported by a late-stage trial involving more than 40,000 adults. Moderna’s vaccine was 26.6% more effective at preventing influenza than a standard-dose flu shot. It also reduced severe cases requiring hospital or urgent care and produced stronger immune responses than a high-dose vaccine in a separate study of older adults. Approval differs slightly between age groups. MFlusiva received traditional approval for adults aged 50 to 64, while its approval for people aged 65 and older was granted under the FDA’s accelerated pathway. Moderna must conduct an additional study to confirm its effectiveness among older patients. The technology could offer an important advantage over traditional flu vaccines. Many existing shots are produced using eggs, a process that can take months and requires manufacturers to select targeted flu strains well before the season begins. An mRNA vaccine can be developed and updated more quickly, potentially allowing it to better match the strains that eventually circulate. For Moderna, however, this is also a business test. Revenue from its Covid vaccine has fallen sharply since the height of the pandemic, leaving the company searching for products that can justify its research spending and rebuild investor confidence. MFlusiva will enter a competitive market with established vaccines from Sanofi, GSK and CSL Seqirus. Moderna must persuade doctors, pharmacies and health systems that its improved trial results are enough to support adoption. The vaccine is also unlikely to make a significant financial contribution immediately because many purchasing decisions for the coming flu season have already been made. Even so, the approval gives Moderna a product aimed at a large and recurring market. Seasonal flu vaccination is needed every year, offering a more predictable opportunity than emergency pandemic demand. MFlusiva will not settle every question surrounding Moderna’s future. It does, however, move mRNA into one of the world’s largest established vaccine markets. The next challenge is proving that scientific success can become a durable commercial business.

Following its historic market debut last week, the aerospace giant Space X has surged to a valuation exceeding $2 trillion, placing it ahead of Tesla in market value and cementing its position among the world’s most valuable publicly traded companies. Wall Street is now watching whether the momentum can continue. Technology stocks moved higher Monday as investors welcomed signs of easing geopolitical tensions and shifted their attention back toward growth-focused sectors. Broader market sentiment improved after reports of a ceasefire agreement between the U.S. and Iran, helping lift risk assets. But the biggest story remains SpaceX. Following its historic market debut last week, the aerospace giant has surged to a valuation exceeding $2 trillion, placing it ahead of Tesla in market value and cementing its position among the world’s most valuable publicly traded companies. SpaceX Overtakes Tesla SpaceX shares finished their first trading session nearly 20% above their IPO price, giving the company a market capitalization of roughly $2.1 trillion. The move pushes SpaceX ahead of Tesla and places it among the elite tier of U.S. corporations by valuation. The rally also expanded the fortune of founder Elon Musk, whose holdings across SpaceX and Tesla have reached unprecedented levels following the company’s public debut. The IPO arrives at a time when investors are pouring capital into companies tied to artificial intelligence, advanced computing, and next-generation infrastructure. Strong demand for SpaceX shares suggests investors remain willing to pay premium valuations for businesses perceived as long-term innovation leaders. Some analysts argue the stock’s valuation is difficult to justify using traditional metrics, while others point to the company’s dominance in satellite communications, launch services, and future AI ambitions as reasons investors are willing to look years ahead. Why It Matters SpaceX’s successful debut could open the door for other high-profile technology companies considering public listings. Market participants are already speculating that major AI firms could follow, creating what may become the next major wave of technology IPOs. If investor enthusiasm remains strong, 2026 could mark the beginning of a new chapter for growth-stock investing.

In a market obsessed with the next shiny critical mineral, Ares Strategic Mining (CSE: ARS) is quietly doing something rarer: turning a fully permitted Utah mine into actual cash-flowing production. The latest investor update makes the case crystal clear. The metallurgical-grade (metspar) lumps plant at the Lost Sheep Mine is in final commissioning. Production is imminent. First shipments are targeted for next month. Roughly 12,000 tonnes of high-grade material already sit stockpiled and ready. Management is eyeing US$20–30 million in annual metspar revenue—achievable well within three years—before the higher-value acid-grade flotation plant comes online in the first half of next year. That second plant is backed by a five-year U.S. Department of Defense contract with a ceiling approaching a quarter-billion dollars, plus an established offtake relationship with the Kremer Group. Fluorspar is the only non-metallic critical mineral the United States still imports 100%. It goes into steel, aluminum, hydrofluoric acid, lithium-ion batteries, refrigerants, semiconductors, and more. China remains a net importer after exhausting its own high-grade reserves. Prices have been rising. Domestic supply is not a nice-to-have; it is strategic. Ares holds a district-scale position across ~6,000 acres of the Spor Mountain range, has already built the bulk of its processing infrastructure, and is advancing a potential NASDAQ uplisting. The company is shifting from pure development spend into self-sustaining revenue. For investors tired of perpetual “near-term production” stories that never arrive, this one is different: the plant is built, the ore is stockpiled, the customers are lined up, and the clock is ticking in weeks, not years. Top-pick highlights Imminent metspar production and first revenue 12,000 tonnes already stockpiled Clear path to $20–30 M annual revenue DoD acid-spar contract + established commercial offtake Fully permitted, infrastructure largely complete Solving a genuine 100% import gap in a critical mineral Watch the full update and judge for yourself: Ares is no longer a story about potential. It is a story about execution – and the timing looks excellent. This is a sponsored article.

The term “pink sheets” historically refers to stocks that are traded over-the-counter (OTC) rather than on established U.S. stock exchanges such as the New York Stock Exchange (NYSE). These stocks represent companies that either cannot meet or choose not to comply with the listing requirements of these major exchanges. Reasons for this might include their small size, being based outside the U.S., or a reluctance to undertake the rigorous and costly process of filing with the Securities and Exchange Commission (SEC). Historic Pink Sheets The term”pink sheets” originated from the distinctive pink-colored paper on which these stocks’ quotes were once printed. Although predominantly viewed as high-risk and speculative, these securities have seen an increase in regulatory oversight over time. The terminology surrounding them has also evolved: in 2008, the pink sheets were officially renamed Pink OTC Markets, and in 2011, this was further changed to OTC Markets Group. Despite these official changes, the term “pink sheets” is still commonly used in the financial industry to refer to these types of stocks. This colloquial usage persists as a nod to their historical roots and distinctive trading characteristics. Understanding the Pink Open Markets The “Pink” designation in the finance world originated from the pink paper used for printing stock price quotes. Although trading is now digital, “pink” still refers to certain over-the-counter (OTC) stocks in conversations. OTC markets, unlike major exchanges, operate through a decentralized network of dealers holding securities to manage trades. These securities are primarily traded on Alternative Trading Systems (ATSs), with two key interdealer systems: the NYSE Group’s Global OTC ATS and OTC Markets’ OTC Link ATS. The OTC Markets Group oversees three key OTC trading venues: OTCQX, OTCQB, and the Pink market. Each marketplace has different financial standards and regulatory scrutiny levels. The Pink market, known for being highly speculative, is the least regulated with minimal financial standards, making it an open market for trading OTC stocks.

Scientists from the Cancer Research UK Scotland Institute and Memorial Sloan Kettering Cancer Centre have discovered a cancer treatment that can identify patients who are more likely to respond to cancer drugs. Funded by Cancer Research UK and published in Nature Cancer, the study reveals new ways to identify patients who could benefit most from immunotherapy testing for mitochondrial DNA mutations (mtDNA). Researchers rewired the DNA of the mitochondria – energy factories found in living cells – to determine cancer responses to treatments that harness the body’s natural defences to attack cancer cells. Found in up to 50% of all cancers, mtDNA mutations cause mitochondrial dysfunction, which affects adenosine triphosphate levels – the source of energy for use and storage at the cellular level – as well as other cellular processes, leading to neuronal loss. Researchers found that tumours with high levels of mtDNA mutations were up to two and a half times more likely to respond to treatment with the immunotherapy drug Opdivo (nivolumab). Bristol Myers Squibb’s Opdivo works by releasing a brake on the immune system to attack cancer cells and is currently used to treat several different cancers, including melanoma, lung cancer, liver cancer and bowel cancer. Scientists believe that they could routinely test for mtDNA mutations to help doctors identify which patients will benefit most from immunotherapy before starting.Findings also suggest that combining treatments that mimic the effect of mtDNA mutations with immunotherapy could make treatment-resistant cancers sensitive to immunotherapy, increasing the chances of successful treatment for multiple types of cancer. Now the subject of a patent filed by Cancer Research Horizon, the technology behind the discovery is currently in the process of being brought to market to allow new treatments to be developed to disrupt the energy sources cancer uses to spread and grow. Dr Iain Foulkes, executive director, research and innovation, Cancer Research UK and chief executive officer, Cancer Research Horizons, said: “Through… Cancer Research Horizons, we’re planning to accelerate this discovery into the clinic and ensure as many patients as possible can benefit.”